Breaking News

IPS Appoints Compliance Manager

By Kristin Brooks | January 31, 2014

Corbin brings 23 years of experience

Scott Corbin has been appointed regional manager of Compliance for the New England region at IPS-Integrated Project Services, Inc. Mr. Corbin has more than 23 years of experience in the biotechnology, medical device and pharma industries, including experience in regulated environments across product development and operations within medical device and biopharma research and manufacturing facilities.
Mr. Corbin joins the company from Luitpold Pharmaceuticals, Inc., where managed technical quality operations. Previously, he held technical leadership positions with Genzyme, Lonza Biologics, and Glaxo/Wellcome. Mr. Corbin is an accredited ASQ Quality Auditor and ISO 13485 Certified Internal Auditor.
“With Scott’s depth of experience, including the manufacture and validation of biologics, medical devices and pharmaceutical products, we anticipate that he will deliver tangible, long-term value for our clients,” said Dave Goswami, PE, chief executive officer and chairman, IPS. “He has demonstrated leadership in delivering innovative and cost effective solutions in validation and quality assurance along with cutting-edge manufacturing and operations expertise. With the addition of Scott, IPS is well-positioned to help achieve strategic and business goals for companies located in New England.”

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision